Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a, Two-Part, Open-Label and Randomized Study to Evaluate the Safety and Efficacy of OD-07656 and of Subsequent Vedolizumab Therapy in Patients With Moderately to Severely Active Ulcerative Colitis

NCT06850727 is registered in ClinicalTrials.gov with Odyssey Therapeutics as lead sponsor.

NCT NCT06850727
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06850727 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a, Two-Part, Open-Label and Randomized Study to Evaluate the Safety and Efficacy of OD-07656 and of Subsequent Vedolizumab Therapy in Patients With Moderately to Severely Active Ulcerative Colitis
Lead sponsor
Odyssey Therapeutics
Phase
Phase 2
Overall status
Recruiting
Start date
June 2, 2025
Completion date
November 30, 2026
Enrollment
57 (estimated)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

uc - ulcerative colitis, ulcerative colitis (uc)